Li WH, Tanimura M, Luo CC, Datta S, Chan L. The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res. 1988;29(3):245–71.
Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 2001;12(3):297–304.
Cohn JS, Tremblay M, Batal R, Jacques H, Veilleux L, Rodriguez C, et al. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 2002;43(10):1680–7.
Malmendier CL, Lontie JF, Grutman GA, Delcroix C. Metabolism of apolipoprotein C-I in normolipoproteinemic human subjects. Atherosclerosis. 1986;62(2):167–72.
Jonas A, Sweeny SA, Herbert PN. Discoidal complexes of A and C apolipoproteins with lipids and their reactions with lecithin: cholesterol acyltransferase. J Biol Chem. 1984;259(10):6369–75.
Soutar AK, Garner CW, Baker HN, Sparrow JT, Jackson RL, Gotto AM, et al. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry. 1975;14(14):3057–64.
Poensgen J. Apolipoprotein C-1 inhibits the hydrolysis by phospholipase A2 of phospholipids in liposomes and cell membranes. Biochim Biophys Acta. 1990;1042(2):188–92.
Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J Lipid Res. 2002;43(12):2136–45.
de Haan W, Out R, Berbée JFP, van der Hoogt CC, van Dijk KW, van Berkel TJC, et al. Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo. Biochem Biophys Res Commun. 2008;377(4):1294–8.
Gautier T, Masson D, Jong MC, de Pais Barros JP, Duverneuil L, Le Guern N, et al. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice. Biochem J. 2005;385(Pt 1):189–95.
Gautier T, Tietge UJF, Boverhof R, Perton FG, Le Guern N, Masson D, et al. Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein. J Lipid Res. 2007;48(1):30–40.
de Barros JPP, Boualam A, Gautier T, Dumont L, Vergès B, Masson D, et al. Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma. J Lipid Res. 2009;50(9):1842–51.
Pillois X, Gautier T, Bouillet B, de Pais Barros JP, Jeannin A, Vergès B, et al. Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease. J Lipid Res. 2012;53(6):1200–9.
Bouillet B, Gautier T, Blache D, de Pais Barros JP, Duvillard L, Petit JM, et al. Glycation of apolipoprotein C1 impairs its CETP inhibitory property: pathophysiological relevance in patients with type 1 and type 2 diabetes. Diabetes Care. 2014;37(4):1148–56.
Ken-Dror G, Talmud PJ, Humphries SE, Drenos F. APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men. Mol Med. 2010;16(9–10):389–99.
CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45(1):25–33.
Geisel MH, Coassin S, Heßler N, Bauer M, Eisele L, Erbel R, et al. Update of the effect estimates for common variants associated with carotid intima media thickness within four independent samples: the Bonn IMT Family Study, the Heinz Nixdorf Recall Study, the SAPHIR Study and the Bruneck Study. Atherosclerosis. 2016;249:83–7.
Hubácek JA, Pitha J, Adámková V, Skodová Z, Lánská V, Poledne R. Apolipoprotein E and apolipoprotein CI polymorphisms in the Czech population: almost complete linkage disequilibrium of the less frequent alleles of both polymorphisms. Physiol Res. 2003;52(2):195–200.
Lauer SJ, Walker D, Elshourbagy NA, Reardon CA, Levy-Wilson B, Taylor JM. Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J Biol Chem. 1988;263(15):7277–86.
Myklebost O, Rogne S. The gene for human apolipoprotein CI is located 4.3 kilobases away from the apolipoprotein E gene on chromosome 19. Hum Genet. 1986;73(4):286–9.
Smit M, van der Kooij-Meijs E, Frants RR, Havekes L, Klasen EC. Apolipoprotein gene cluster on chromosome 19. Definite localization of the APOC2 gene and the polymorphic Hpa I site associated with type III hyperlipoproteinemia. Hum Genet. 1988;78(1):90–3.
Davison PJ, Norton P, Wallis SC, Gill L, Cook M, Williamson R, et al. There are two gene sequences for human apolipoprotein CI (apo CI) on chromosome 19, one of which is 4 kb from the gene for apo E. Biochem Biophys Res Commun. 1986;136(3):876–84.
Kim E, Xie S, Yeh SD, Lee YF, Collins LL, Hu YC, et al. Disruption of TR4 orphan nuclear receptor reduces the expression of liver apolipoprotein E/C-I/C-II gene cluster. J Biol Chem. 2003;278(47):46919–26.
Mak PA, Laffitte BA, Desrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem. 2002;277(35):31900–8.
Dahabreh DF, Medh JD. Activation of peroxisome proliferator activated receptor-gamma results in an atheroprotective apolipoprotein profile in HepG2 cells. Adv Biol Chem. 2012;2(3):218–25.
Subramanian S, Gottschalk WK, Kim SY, Roses AD, Chiba-Falek O. The effects of PPARγ on the regulation of the TOMM40-APOE-C1 genes cluster. Biochim Biophys Acta Mol Basis Dis. 2017;1863(3):810–6.
Vrins CLJ, Out R, van Santbrink P, van der Zee A, Mahmoudi T, Groenendijk M, et al. Znf202 affects high density lipoprotein cholesterol levels and promotes hepatosteatosis in hyperlipidemic mice. PLoS ONE. 2013;8(2):e57492.
Fernandes GW, Bocco BMLC, Fonseca TL, McAninch EA, Jo S, Lartey LJ, et al. The Foxo1-inducible transcriptional repressor Zfp125 causes hepatic steatosis and hypercholesterolemia. Cell Rep. 2018;22(2):523–34.
Wassef H, Bernier L, Davignon J, Cohn JS. Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells. J Nutr. 2004;134(11):2935–41.
Cyr Y, Wassef H, Bissonnette S, Lamantia V, Davignon J, Faraj M. WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects. J Lipid Res. 2016;57(6):1074–85.
Bouchard C, Dubuc G, Davignon J, Bernier L, Cohn JS. Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells. Atherosclerosis. 2005;178(2):257–64.
Knott TJ, Robertson ME, Priestley LM, Urdea M, Wallis S, Scott J. Characterisation of mRNAs encoding the precursor for human apolipoprotein CI. Nucleic Acids Res. 1984;12(9):3909–15.
Jackson RL, Sparrow JT, Baker HN, Morrisett JD, Taunton OD, Gotto AM Jr. The primary structure of apolopoprotein-serine. J Biol Chem. 1974;249(16):5308–13.
Shulman RS, Herbert PN, Wehrly K, Fredrickson DS. Thf complete amino acid sequence of C-I (apoLp-Ser), an apolipoprotein from human very low density lipoproteins. J Biol Chem. 1975;250(1):182–90.
Bondarenko PV, Cockrill SL, Watkins LK, Cruzado ID, Macfarlane RD. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein. J Lipid Res. 1999;40(3):543–55.
Rozek A, Sparrow JT, Weisgraber KH, Cushley RJ. Conformation of human apolipoprotein C-I in a lipid-mimetic environment determined by CD and NMR spectroscopy. Biochemistry. 1999;38(44):14475–84.
McPherson A, Larson SB. The structure of human apolipoprotein C-1 in four different crystal forms. J Lipid Res. 2019;60(2):400–11.
Segrest JP, Jackson RL, Morrisett JD, Gotto AM. A molecular theory of lipid-protein interactions in the plasma lipoproteins. FEBS Lett. 1974;38(3):247–58.
Segrest JP, Feldmann RJ. Amphipathic helixes and plasma lipoproteins: a computer study. Biopolymers. 1977;16(9):2053–65.
Meyers NL, Wang L, Gursky O, Small DM. Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid/water interfaces. J Lipid Res. 2013;54(7):1927–38.
Cushley RJ, Okon M. NMR studies of lipoprotein structure. Annu Rev Biophys Biomol Struct. 2002;31:177–206.
Carlson LA, Holmquist L. Concentrations of apolipoproteins B, C-I, C-II, C-III and E in sera from normal men and their relation to serum lipoprotein levels. Clin Chim Acta. 1982;124(2):163–78.
Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of apolipoproteins C-I and C-II in human plasma by separate electroimmunoassays. Clin Chem. 1981;27(4):543–8.
Fuior EV, Gafencu AV. Apolipoprotein C1: its pleiotropic effects in lipid metabolism and beyond. Int J Mol Sci. 2019;20(23):E5939.
Riesen WF, Sturzenegger E. Enzyme-linked immunosorbent assay for apolipoprotein C-I. J Clin Chem Clin Biochem. 1986;24(10):723–7.
Cohn JS, Tremblay M, Boulet L, Jacques H, Davignon J, Roy M, et al. Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism. Atherosclerosis. 2003;169(1):63–70.
Lemesle G, Chouraki V, de Groote P, Turkieh A, Beseme O, Drobecq H, et al. Apolipoprotein proteomic profiling for the prediction of cardiovascular death in patients with heart failure. Proteomics Clin Appl. 2020;14(6):e2000035.
Fredrickson DS, Lux SE, Herbert PN. The apolipoproteins. Adv Exp Med Biol. 1972;26:25–56.
Gautier T, Deckert V, Aires V, Le Guern N, Proukhnitzky L, Patoli D, et al. Human apolipoprotein C1 transgenesis reduces atherogenesis in hypercholesterolemic rabbits. Atherosclerosis. 2021;320:10–8.
留言 (0)